Teva announces new patient access program with Direct Relief

Teva (TEVA) Pharmaceuticals announced the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients in the United States free of charge. Teva will make two inhaler products available through this program: generic versions of the AirDuo RespiClick and ProAir HFA. Teva will donate the inhalers to Direct Relief for distribution by request to free & charitable clinics, to then be dispensed to uninsured patients served by these clinics. The program will continue for a minimum of three years to ensure reliable and continuous supply to these patients. In addition to donating the inhalers, Teva will make a cash donation to Direct Relief to cover the costs of administering this program.